Landscape Analysis of Human Papillomavirus (HPV) Prophylactic Vaccine Clinical Trials in China Based on the NMPA Database
HPV vaccine clinical trials in China have made significant progress, with most at a crucial stage, featuring diverse vaccine types and high-quality designs. However, more efforts are needed to promote the development and approval of the HPV vaccine by increasing tertiary hospitals' qualifications for conducting clinical trials, establishing a government-led non-profit third-party quality control platform and increasing research and development investment to ensure insurance coverage.
Authors
- Yanmei Huang (ORCID: https://orcid.org/0000-0001-8862-7489)
- Gaoli He (ORCID: https://orcid.org/0009-0008-2447-7467)
- Xiaoyan Zhang (ORCID: https://orcid.org/0000-0002-1815-5188)
- Tao Zeng (ORCID: https://orcid.org/0000-0002-3349-0291)
- Lin Yuan (ORCID: https://orcid.org/0000-0002-6583-7333)
- Hua Jiang (ORCID: https://orcid.org/0000-0003-4913-5793)
- Hong Lü (ORCID: https://orcid.org/0000-0001-5593-6533)
Institutions
- Obstetrics and Gynecology Hospital of Fudan University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/dddt.s562608
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Hospital Development Center